학술논문
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
Document Type
Article
Author
O'Gorman, P.; Saeed, K.; Scott, K.; Laubach, J.P.; DiPietro, H.; Cummings, K.; Savell, A.; Masone, K.; Guerrero Garcia, T.; Bianchi, G.; Richardson, P.G.; O'Dwyer, M.E.; Krawczyk, J.; Yee, A.J.; Gilligan, O.; Cahill, M.R.; Rosenblatt, J.; Quinn, J.; Murphy, P.T.; Perera, M.R.; Crotty, G.M.; Hayden, P.J.; Browne, P.; O'Leary, H.M.; O'Keeffe, D.; Hennessy, B.J.; Dowling, P.; Tierney, C.
Source
In: American Journal of Hematology . (American Journal of Hematology, May 2022, 97(5):562-573)
Subject
Language
English
ISSN
10968652
03618609
03618609